US LNG exports surge but will buyers in China turn up?
Rajeev Singh, the Chief Executive Officer of Accolade, Inc. (NASDAQ:ACCD), recently executed a stock transaction involving the sale of 490 shares of the company’s common stock. The sale, which took place on March 11, 2025, was conducted at an average price of $6.965 per share, amounting to a total value of $3,412. This transaction was carried out to cover tax withholding obligations related to the vesting of restricted stock units (RSUs), as per a mandatory sell-to-cover arrangement. The transaction occurs as Accolade’s stock shows strong momentum, with a remarkable YTD return of over 103% and current trading price of $6.98. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value estimate.
In addition to the sale, Singh acquired 1,650 shares of common stock on March 10, 2025. These shares were acquired at no cost as a result of the conversion of RSUs. Following these transactions, Singh holds a direct ownership of 828,447 shares of Accolade’s common stock. Additionally, Singh has indirect ownership of 651,619 shares through Avanti Holdings, LLC, where he is a partner with voting and investment power. With a market capitalization of $572.31M and a six-month price return of 77%, the company shows promising market performance. InvestingPro subscribers can access 7 additional key insights about Accolade’s financial health and market position.
In other recent news, Accolade Inc . announced its acquisition by Transcarent in a deal valued at $621 million, with Accolade shareholders set to receive $7.03 per share. This acquisition, which represents a significant premium over Accolade’s previous closing stock price, is expected to be finalized in the second quarter of 2025. Following the announcement, Stifel downgraded Accolade’s stock from Buy to Hold, adjusting the price target to align with the offer price of $7.03, indicating a more cautious outlook on the company’s future stock performance. Meanwhile, Raymond (NSE:RYMD) James also adjusted its rating from Outperform to Market Perform after the acquisition announcement, noting the transaction’s revenue and EBITDA multiples.
On a different note, Truist Securities maintained a Buy rating on Accolade, with a price target of $7.50, emphasizing the synergistic potential of the merger with Transcarent. The merger is expected to enhance Accolade’s market position by combining its healthcare solutions with Transcarent’s offerings. Analysts highlighted that the combined entity will serve over 1,400 employer and payer clients, creating valuable cross-selling opportunities. Accolade has withdrawn its previous financial guidance for the fiscal year but plans to report third-quarter financial results within the previously provided guidance range.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.